Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or
epitopes. In the last few decades, BsAbs have been developed within the context of cancer …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …

In the era of immunotherapeutic control of cancers, many advances in biotechnology,
especially in Ab engineering, have provided multiple new candidates as therapeutic …

Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of
pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and …

Harnessing the power of the human immune system to treat cancer is the essence of
immunotherapy. Monoclonal antibodies engage the innate immune system to destroy …

Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to
immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific …

Immunotherapy has redefined the treatment of cancer patients and it is constantly
generating new advances and approaches. Among the multiple options of immunotherapy …

Monoclonal antibody-based targeted therapy has greatly improved treatment options for
patients. However, long-term efficacy of such antibodies is limited by resistance …

Over the past decades advances in bioengineering and expanded insight in tumor
immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs …

Highlights•Opportunities and challenges of T-biAbs in hematologic and solid malignancies.•
Conventional versus in situ delivery of T-biAbs.•T-biAbs versus CAR-Ts in cancer …